Omega-3 and Omega-6 Fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort

Thompson, A.,*1,2 Jones, H.J.,*3,4 Heron, J.,3 Hibblen, J.,5 Sullivan S.,3,6 Zammit, S.3,4,7

1 Division of Mental Health and Wellbeing, University of Warwick, UK

2 Orygen, the Centre of Excellence in Youth Mental Health, 35 Poplar Rd, Parkville, VIC 3250

3 Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK

4 NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol, UK

5 Laboratory of Membrane Biochemistry and Biophysics; Section of Nutritional Neuroscience, National Institute for Health, Bethesda, USA

6 NIHR CLAHRC West, Whitefriars, Lewins Mead, Bristol, UK

7 MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK

* Joint first authors

Address for Correspondence: Andrew Thompson, Orygen, the Centre of Excellence in Youth Mental Health, 35 Poplar Rd, Parkville, VIC 3052, Australia.

Tel: +61 (0)3 99669100 Email: Andrew.thompson@orygen.org.au
Abstract

**Background:** Long Chain Polyunsaturated Fatty Acid (PUFA) levels have been implicated in the pathology of psychotic disorders. We investigated the relationship between childhood PUFA levels and later psychotic experiences (PE’s) in a large birth cohort. **Methods:** Plasma levels of Ω-3 and Ω-6 fatty acids (FA’s) were assayed at ages 7 and 16 years. PE’s were assessed at ages 12 and 18 years using a semi-structured interview. Primary outcome was any PE’s at 18 years; sensitivity analyses examined incident PE’s between ages 12 and 18 years, persistent PE’s (at 12 and 18) and psychotic disorder at 18 years. Genetic instruments for Ω-3 and Ω-6 were derived and used in a multivariable Mendelian Randomization analysis. **Results:** Higher levels of Ω-6 FA’s AA, OA and AdA at age 7 years were weakly associated with a reduced risk for PE’s at 18 years, however, effect sizes were small and attenuated after adjusting for confounders (strongest evidence for OA; adjusted OR, 0.842; 95% CI, 0.711, 0.998; p, 0.048). Total Ω-6 levels at age 16 years were associated with an increased odds of psychotic disorder at age 18 years. However, there was no association between Ω-6/Ω-3 ratio and psychosis outcomes, nor with genetic instruments of total Ω-3 or Ω-6 levels. **Conclusions:** There is no strong evidence that total plasma Ω-3 FA levels or Ω-6/Ω-3 ratios in childhood and mid-adolescence are associated with increased risk for PE’s or psychotic disorder, but very marginal evidence that alterations in the Ω-6 pathway at developmental time points might influence risk.
Footnote

AA, arachidonic acid (20:4n-6); AdA, docosatetraenoic acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic acid (trivial name osbond acid; 22:5n-6)

1. Introduction

The role of nutritional factors in mental health has recently received greater research focus (Sarris et al., 2015). A recent systematic review reported a consistent trend across studies of a relationship between good-quality diet and better child and adolescent mental health (O'Neil et al., 2014), including common psychiatric disorders such as depression and anxiety, but also psychotic disorders such as schizophrenia. An especially important nutrient group for brain development are the essential fatty acids, including the long chain polyunsaturated fatty acids (PUFAs). Long chain PUFAs such as omega-3 are involved in the neuromodulation of neurotransmitter uptake, degradation and synthesis and receptor binding (Dyall, 2015; Liu et al., 2015). They also enhance cell membrane fluidity and neurogenesis via up regulation of Brain-Derived Neurotrophic Factor (BDNF) (Mischoulon and Freeman, 2013). Omega-3 and omega-6 fatty acids also seem to have distinct roles in the inflammatory pathway (Simopoulos, 2002), with omega-3 PUFAs such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) involved in the anti-inflammatory pathway, and omega-6 PUFAs such as arachidonic acid (AA) and docosapentaenoic acid (DPA) appearing to be pro-inflammatory (Liu et al., 2015). The balance between
omega-6 levels and omega-3 levels has been proposed to be important in a number of inflammatory diseases (Simopoulos, 2002). It can be measured from dietary intake or biological measures and can be calculated by the ratio of mean n-6 and n-3 fatty acid levels (Sheppard and Cheatham, 2013) or of total levels (Thesing et al., 2018). Inflammatory processes have long been proposed as a pathological mechanism in psychosis (Khandaker et al., 2015), supported by evidence from clinical studies of microglial activation (Cannon, 2016), and epidemiological studies of prenatal and childhood infections (Karlsson and Dalman, 2020), autoimmune disorders (Jeppesen and Benros, 2019), and proinflammatory cytokines (Momtazmanesh et al., 2019).

PUFA abnormalities have been found in a number of studies with patients with psychotic disorders. Low levels of omega-3 (and omega-6) fatty acids have also been found in the red cell membranes of patients with schizophrenia (Peet et al., 1995), although this is not consistent across all studies (Medema et al., 2016). Associations between psychotic symptoms and lowered levels of some omega-3 (Docosapentaenoic acid, DPA) and 6 fatty acids (γ-linolenic and docosadienoic acids) in red cell membranes have been found in “at risk for psychosis” groups (Kim et al., 2016). Omega-6/omega-3 dietary intake, possibly reflecting the balance between neuroprotective and proinflammatory pathways, is also altered in both first episode psychosis and those presenting with clinical high risk for psychosis (Pawełczyk et al., 2015). A causal role of PUFA’s in development of schizophrenia is supported by a trial that demonstrated a beneficial effect of relatively high dose omega-3 supplementation (750mg EPA/DHA) on risk of
transition to psychosis in a clinical high risk for psychosis sample (Amminger et al., 2010). A more recent replication trial did not demonstrate an significant overall effect (McGorry et al., 2017), however, increases of the n-3 index, EPA, and DHA in this trial predicted less severe psychopathology and better functioning (Amminger et al., 2020). The same group found that PUFA supplementation in a clinical high risk group may act by normalizing intracellular phospholipase A2 activity and δ-6-desaturase-mediated metabolism of omega-3 and omega-6 PUFAs (Smesny et al., 2014). The researchers hypothesized that omega-3 fatty acid supplementation had an effect on cell membrane stability and, through this and other pathways, acted as a neuroprotector (Amminger et al., 2015).

If levels of PUFA’s are altered in patients at risk for psychosis and predict transition to psychosis, then it would be useful to investigate levels of long chain PUFAs in childhood to investigate whether levels or ratio differences at an early age are psychosis risk factors. Cohort studies are the strongest observational study design for investigating the effects of PUFA levels on development of psychopathology, including psychotic disorder. As psychotic disorder is a relatively rare outcome, the presence of psychotic experiences, especially if persistent or associated with impairment, may be a good proxy for psychosis risk. Clinically diagnosed psychosis has a lifetime prevalence of around 3% (Perala et al., 2007), but psychotic experiences and sub-clinical expressions are estimated to occur in approximately 7.5-17% of the general population (Kelleher et al., 2012a; Zammit et al., 2013). This broader spectrum of psychosis can also
result in significant distress, functional impairment, increased suicidal behaviour (Kelleher et al., 2012b) and increases the risk of developing a full-blown psychotic disorder in adulthood (Fisher et al., 2013; van Os et al., 1999) especially in individuals whose psychotic experiences persist over time (Dominguez et al., 2011; Kaymaz et al., 2012).

One study in a large cohort of Swedish women aged 30-49 found that the intake of fatty acids at baseline (as measured by a food frequency questionnaire) was related to the levels of self-reported psychotic experiences a decade later (Hedelin et al., 2010). This was the case for both omega-3 and omega-6 dietary fatty acid levels, but the relationship was non-linear and a high fatty acid intake level was also associated with an increased risk of psychotic experiences as well as low levels. This study was in an older population, with potential for residual confounding and used a dietary questionnaire, not biological levels, thus being prone to measurement error (Hedelin et al., 2010). There have been no reports investigating childhood PUFA levels and psychotic experiences.

To address some of these issues we aimed to investigate the association between childhood blood levels of omega-3 and omega-6 fatty acids levels and late adolescent risk of developing psychotic experiences and other psychosis outcomes including psychotic disorder in a large birth cohort. This included investigating genetic proxies of these levels using Mendelian Randomization to address residual confounding and reverse causation. We specifically
hypothesised that an altered omega-6/omega-3 ratio in childhood would be associated with an increase in late adolescent psychotic experiences.

2. Methods

2.1 Participants

The Avon Longitudinal Study of Parents and Children (ALSPAC) is a UK birth cohort study (Boyd et al., 2013; Fraser et al., 2013). Pregnant women resident in Avon District with an expected delivery date between 1\textsuperscript{st} April 1991 and 31\textsuperscript{st} December 1992 were approached to participate in the study, leading to the inclusion of 14,775 live births with 14,701 of these alive at 1 year of age. This analysis is based on 4720 children who completed the Psychosis-LIKE Symptoms interview (PLIKSi) at approximately 18 years of age. Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees (http://www.bristol.ac.uk/alspac/researchers/research-ethics/). Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.

2.2 Outcome Variables

2.21 Primary outcome
Psychotic experiences: The PLIKSi (Horwood et al., 2008; Zammit et al., 2013) is a semi-structured face-to-face interview, rated according to guidelines for the Schedules for Clinical Assessment in Neuropsychiatry version 2.0 (SCAN 2.0), which elicits key psychotic experiences covering hallucinations (visual and auditory), delusions (spied on, persecution, thoughts read, reference, control, grandiosity and other unspecified delusions), and experiences of thought interference (thought broadcasting, insertion and withdrawal). The PLIKSi interview was carried out in the cohort at the age of 12 and the age of 18. The average kappa values for inter-rater and test-retest reliability were 0.83 and 0.76 at the age of 18 (Zammit et al., 2013). Further detail on the instrument is available elsewhere (Zammit et al., 2013) as well as further detail on this data (Horwood et al., 2008; Zammit et al., 2013). The primary outcome was ≥1 of the PLIKSi experiences suspected or definitely present at age 18 and not attributable to sleep, fever or substance use.

2.22 Sensitivity analyses

We also examined three other psychosis outcomes, including some that are potentially more clinically meaningful but less common. These were: a) at least 1 suspected or definite psychotic experience incident by age 18 (i.e. not present at 12), b) at least 1 suspected or definite psychotic experience present at both age 12 and age 18 (persistent PLIKSi), and c) psychotic disorder at age 18. We classified individuals as having a psychotic disorder if they reported definite psychotic experiences not attributable to the effects of sleep or fever that had occurred at least once per month over the previous 6 months and either caused
severe distress, had a markedly negative impact on social or occupational function, or led to help seeking (see (Zammit et al., 2013)).

2.3 Independent Variables

2.31 Omega-3/6 PUFA levels

Overall plasma PUFA levels and levels of individual omega-3 and omega-6 fatty acids were available from non-fasting blood samples taken from the children at mean 7.5 years (5576). From these samples, plasma was obtained after centrifugal separation and frozen immediately. All samples were stored at −70 °C, thawed once to obtain a 100 μl aliquot, shipped airfreight on dry ice to Rockville MD and thawed a second time for analysis. Transmethylation of lipids with acetyl chloride and methanol was performed using a simplified method based on the Lepage and Roy procedure (Lepage and Roy, 1986) using a high throughput automated method (Masood and Salem, 2007). Internal calibration was conducted by adding internal standards to each assay. A second standard was used to quantify the exact amount of internal standard in every batch for ongoing assay of experimental variability. Freedom Evo Instrument 200 (TECAN Trading AG, Switzerland) was utilised for the automatic transmethylation and extraction of fatty acids employing the customised control and automation software (EVOware V.2.0, SP1, Patch3). Gas chromatography 6890 Plus LAN system (Agilent Technologies, Inc, Santa Clara, California, USA) coupled with a fused-silica, narrow-bored DB-FFAP capillary column (Agilent 127-32H2, 15 m×0.1 mm ID×0.1 μm film thickness) which was used for chromatographic separation of the fatty acid methyl esters as reported previously (Masood and
Salem, 2007). The assay was linear in the range of 1–600 μg/ml plasma. The within and between day imprecision was 3.26±1.2% and 2.95±1.6% for fatty acid concentrations. Assays were undertaken in 2009–2010. In all, 23 FAs were measured including 12 polyunsaturates (Golding et al., 2012).

Summary fatty acids levels and some specific individual fatty acids (DHA and LA) were also measured at age 16 years using a high-throughput Nuclear Magnetic Resonance (NMR) metabolomics platform (Soininen et al., 2015; Soininen et al., 2009). Metabolite data were assessed on fasting (minimum 6-hours) plasma. All fatty acid levels were expressed as percentage of total fatty acids and standardized before analyses.

A summary of the available fatty acid measures are shown in Table 1 and the omega-3 and omega-6 metabolic pathways are shown in Figure 1.

2.4 Genetic data

Following quality control assessment and imputation, genetic data was available for 8252 ALSPAC individuals. For further information on the genetic data please refer to the online supplementary methods.
2.41 Fatty acid genetic instruments

Due to competition for the same elongases and desaturases during omega-6 and omega-3 PUFA biosynthesis, it is difficult to disentangle the specific effects of omega-3 from omega-6 on an outcome. One approach that can be used to attempt to overcome this is by using genetic instruments for omega-3 and omega-6 FA levels within a multivariable analysis. This method, known as MultiVariable Mendelian Randomization (MVMR), is an extension of single exposure Mendelian randomization whereby genetic variants that reliably predict one exposure variable, but do not influence the outcome through any other pathway, are used as instrumental variables in estimating the true causal effect of the exposure on the outcome (Davey Smith and Hemani, 2014).

Genetic instruments were derived using summary statistics from the recent Kettunen et al. (2016) meta-analysis of genome-wide association studies (GWAS) of blood levels of DHA, LA, total omega-3 and total omega-6 fatty acids measured using a high-throughput NMR metabolomics platform in up to 24,925 individuals (Kettunen et al., 2016). Based on the GWAS meta-analysis summary statistics, a list of SNPs that were associated with total omega-3 and total omega-6 fatty acid levels at a genome-wide level of significance (p value ≤ 5e-8) was extracted. Further information on the genetic instruments please refer to the online supplementary methods and Supplementary Table 1.

2.5 Confounders
For the non-genetic analyses, the following confounders were able to be considered due to their potential influence on the exposure and outcome:

Gender; Ethnic group; Highest Parental Social Class; Maternal Education (A levels/degree or equivalent (higher education) v O-level/CSE’s (Certificate of Secondary Education - lowest UK school-leaving qualifications)); Birth Weight; Family Adversity Index ((FAI) multiple family risk factors were assessed during pregnancy with the Family Adversity Index (Bowen, 2005); Body Mass Index (BMI) at 7 and at 16 years (The child’s BMI was calculated at the same clinic when the blood sample were taken for the FA analysis); Energy intake at 7 and at 13 years (The child’s overall energy intake was calculated from the completion of the Food Frequency Questionnaire as part of the interview ages 7 and 13 years). Please see supplementary methods for further details of confounders and Supplementary Table 2 for number of individuals with available data on each confounder and the proportion who also had available psychotic experience data.

2.6 Statistical Analyses

2.61 Observational analyses

Logistic regression was performed to assess the association between fatty acid plasma levels in ALSPAC at age 7 and age 16 years and psychotic experiences outcomes at age 18 years. Results are presented for unadjusted and adjusted analyses, where potential confounders have been included as covariates within the logistic regression. We additionally tested the associations between each genetic instrumental variable for omega-3 and omega-6 FA fatty acid levels in
ASLPAC and psychotic experiences at age 18 years using logistic regression. All statistical analyses were performed using Stata (Version 15.1; StataCorp LP, College Station, TX, USA).

2.62 Mendelian randomization

A two-stage least squares MVMR was implemented using the ivreg2 (Baum et al., 2002) command in STATA v14.2 with robust standard errors. The strength of the instrumental variables used in the analysis was assessed using the Sanderson-Windmeijer conditional F test of excluded instruments (Sanderson and Windmeijer, 2016) which tests if the genetic instruments strongly and jointly predict both exposures in the outcome model. Genetic instruments with an F-statistic of 10 or less are generally deemed to be weak.

3. Results

3.1 Description of the sample

The frequencies of psychotic experiences in the cohort and in those with PUFA data are shown in Table 2. Rates were similar in those with and without PUFA data. The summary statistics for the fatty acid levels at 7 and 16 years are shown in Supplementary Table 3. PUFA levels were available for 5565 children at age 7 years and 3356-3360 children at age 16 years.

Insert Table 2
3.2 Association of PUFA plasma levels at 7 years and psychotic experiences at 18 years

In the unadjusted analyses there was weak evidence that higher levels of omega-6 AA, AdA and OA were associated with a decreased odds of psychotic experiences at age 18 years (AA: odds ratio (OR), 0.853; 95% confidence interval (CI), 0.728, 0.999; p, 0.049; AdA: OR, 0.826; 95% CI, 0.702, 0.972; p, 0.021; OA: OR, 0.822; 95% CI, 0.697, 0.970; p, 0.020). The CI included the null for all but one of the adjusted associations between fatty acid levels at age 7 years (OA) and psychotic experiences at age 18 years (OA: adjusted OR, 0.842; 95% CI, 0.711, 0.998; p, 0.048) (see Table 3).

Insert Table 3

3.3 Association of fatty acids blood levels at 16 years and psychotic experiences at 18 years

In the unadjusted analyses higher DHA levels were associated with a decreased risk of psychotic experiences (OR, 0.871; 95% CI 0.736, 1.032; p, 0.110) but the CI’s include the null and this was further attenuated when adjusted for potential confounders (see Table 4).

Insert Table 4
3.4 Sensitivity analyses

We performed sensitivity analyses examining different psychosis outcomes including more stringent/clinically-relevant psychosis outcomes. When the outcome excluded those who reported psychotic experiences at age 12 years, (incident psychotic experiences) an association was seen for higher levels of omega-6 AA, AdA and OA and there was weak evidence that lower AA:EPA ratio at age 7 years increased the odds of reporting psychotic experiences (Supplementary Table 4). Higher LA and total omega-6 levels at age 16 years were associated with an increased odds of psychotic disorder at age 18 years, with evidence slightly weakening in the adjusted analysis, especially for LA (Supplementary Table 5).

3.5 Association of fatty acids genetic instruments and psychotic experiences

The allelic scores (weighted and unweighted) acted as stronger instruments for total omega-3 and total omega-6 fatty acid measures at age 16 years than using the individuals SNPs as instruments (Table 5); however, no Sanderson-Windmeijer F-statistic exceeded 10 indicating that the genetic instruments were weak. There was no strong evidence that instrumental variables for levels of omega-3 or omega-6 were associated with psychotic experiences at 18 years of age, nor the other secondary psychosis outcomes (Table 5 and Supplementary Table 6).

Insert Table 5
4. Discussion

The study aimed to investigate the association between childhood plasma levels of long chain PUFAs and development of psychotic experiences in late adolescence. Overall, omega-3 and omega-6 fatty acids levels taken at 7 and 16 years were not strongly associated with any of the psychotic outcomes examined. When examining our primary outcome, there was weak evidence that higher levels of the omega-6 fatty acid OA and AdA at age 7 years were associated with a decreased risk of psychotic experiences but only the OA association survived adjustment of confounders and effect sizes were small. When examining other psychosis outcomes, there was stronger evidence of association between OA, AdA and also AA at age 7 years, and of a higher AA (omega-6):EPA (omega-3) ratio at this age, with reduced risk of incident psychotic experiences between ages 12 and 18 years. There was also very weak evidence that total omega-6 fatty acid levels at 16 years were associated with increased risk of psychotic disorder. In the Mendelian randomization analysis there was no evidence of association between GWAS-based instrumental variables for total omega-3 and omega-6 levels and psychotic experiences at 18 years.

The majority of studies in patients with established psychosis have found a reduction in PUFA levels, especially DHA, DPA and AA (Hoen et al., 2013). Authors have suggested that these results could be secondary to antipsychotic treatment although some studies have found reduced levels in antipsychotic
naive patients (Reddy et al., 2004). However, it is unclear if these PUFA changes in these populations with an established psychotic disorder reflect a propensity to poorer response to inflammation or even an early response to inflammation or a marker of oxidative stress. Cohort studies or studies in at risk groups are therefore key to try to disentangle these effects but there is very limited data on PUFA levels in patients prior to the onset of psychosis or psychotic experiences. The only cohort study in the extant literature of which we are aware reported that higher levels of omega-3 and omega-6 as measured by dietary intake were associated with a reduced risk of later psychotic experiences (Hedelin et al., 2010). The associations were reverse J-shaped with the strongest reduced risk for an intermediate intake of fish or PUFA (Hedelin et al., 2010).

In our study, there was no evidence that higher plasma levels of the omega-3 PUFA DHA in late adolescence may be protective against broad psychotic experiences. However, whilst higher levels of a number omega-6 PUFAs in childhood appeared to be protective against psychotic experiences, we also found in our sensitivity analyses that higher levels of omega-6 PUFAs in adolescence appeared to increase the risk for developing a psychotic disorder. These findings are not consistent with the suggestion that overactivity of the pro-inflammatory omega-6 pathway may be propsychotic and overactivity of the anti-inflammatory omega-3 pathway may be antipsychotic (Amminger et al., 2010), although the structure of the omega-6/omega-3 pathways suggests that relationships of these PUFAs with psychopathology may be highly complex and that studying their ratio may be more informative. The omega-6/omega-3 plasma ratio (expressed through dietary levels) that has been reported to be
altered/elevated in patients at risk for psychosis (Pawełczyk et al., 2015) compared to healthy controls, was not associated with the psychosis outcomes in our study.

There are a number of possible explanations for this. Firstly, PUFA levels may be differentially important at specific periods of development. For example, any potential neuroprotective balance of omega-6/omega-3 PUFAs might be particularly important in guarding against psychosis risk in the adolescent brain when synaptic pruning is occurring in brain areas believed to be key in psychosis, such as the prefrontal cortex and limbic structures. This could also be why omega-3 fatty acid supplementation may be relatively more effective in younger at-risk groups than in populations with established psychosis, who are generally older.

Secondly, it could be that any early dysfunction in PUFA metabolism is actually located in different places in the pathway and later deficiencies represent a potential compensatory or downstream effect. The omega-6 and omega-3 pathways are not independent of each other and any enzyme deficiency or dietary deficiency will have an effect on other parts of the pathway. This is the reason why we chose not to look at individual PUFA levels in our MR approach but examined the overall effects of the pathways using total levels.

Thirdly, the plasma levels at ages 7 and 16 years were measured differently, with levels at age 16 years taken after 6 hours fasting and levels at age 7 years non-fasting. We are also aware that we have only examined PUFA levels in isolation
and these differences might represent the downstream effect of other overlapping processes such as eicosanoids and other inflammatory pathways. For example, a previous study in this cohort reported higher levels of inflammatory cytokines Interleukin 6 and C Reactive Protein to be related to psychosis (Khandaker et al., 2014), and there are a number of other factors that influence these pathways (Horrobin et al., 1994). We also did not examine omega 9 PUFA levels, as these were not available in the cohort. More research is needed into the interplay between PUFA levels, PUFA metabolism, pro and anti-inflammatory eicosanoids and other inflammatory proteins and risk for developing psychotic symptoms and psychotic disorder.

The results of the MR approach also did not demonstrate any clear associations between these genetic proxies of PUFA levels and psychotic experiences. This leads us to have more certainty that there is not a clear relationship that is confounded by a factor we were not able to adjust for. MR is a useful tool in areas where there are clear genetic variants in biological pathways (Davey Smith and Hemani, 2014). We have examined overview levels of total PUFA levels in isolation in this MR analysis and not specific omega 3 FAs such as EPA or DHA that are used in supplementation, nor omega-6/omega-3 ratios.

4.1 Strengths and Limitations

The strengths of the research are the large dataset, the robust measurements both of psychotic experiences and PUFA levels (at 2 time points), and the ability
to adjust for multiple confounders. There is likely to be no or very minimal
antipsychotic use prior to the measure of PLIKS at 18 years (this is a non-clinical
population). We have also performed an MR analysis to attempt to specifically
address unspecified confounding and reverse causation effects.

Although the sample size is large, there is a considerable amount of missing data
from the original cohort and there are relatively small numbers for some of the
secondary psychosis outcomes, meaning the results for these outcomes should
be interpreted with this caveat. For secondary outcomes such as psychotic
disorder that sample is still below the expected age of peak incidence. There a
number of other potential confounders such as cannabis use, cigarette smoking
and childhood trauma as well as information on dietary supplementation and
other general nutritional factors that were not adjusted for. The numbers are
also relatively small for the MR analysis.

The use of plasma fatty acid levels and not red blood cell membrane (RBC) levels
or brain cell membrane levels is also a potential weakness. The membrane
hypothesis of schizophrenia posits that there are potential alterations in the cell
membrane structure (Horrobin, 1999; Horrobin et al., 1994) and we are unable
to examine this in this cohort. Although there is often considerable correlation
between plasma PUFA levels and those measured in RBC membranes (Sun et al.,
2007), plasma levels are more sensitive to fluctuations in diet and recent intake
whereas RBC levels reflect long term fatty acid intake (Harris and Thomas,
2010). There are some measures of RBC PUFA’s in the ALSPAC cohort although
the sample with data is small (just over 500) and the samples were of cord blood
and may be mixed fetal and maternal samples; therefore, a meaningful analysis
was not possible. It is also necessary to mention that the assays used to measure PUFA levels differ by age (gas chromatography at 7 years vs. NMR at 16 years). Although units were standardised before analyses, the sensitivity of gas chromatography is superior to NMR. The PUFA levels at 7 years were also non-fasting as opposed to the levels at 16 years being 6 hours fasting. We note the MR analysis is likely to give a longer-term proxy of FA levels as an intermediate variable that is not susceptible to fluctuation in diet and intake. We have also not measured eicosanoid levels in this analysis and how these relate to the PUFA levels.

4.2 Clinical implications

There is no clear evidence of specific alterations in PUFA metabolism prior to the onset of psychotic symptoms or psychotic disorder in our findings. If PUFA's are protective against psychosis inset, any potential mechanism of protection and the timing of any protection remains unclear or whether changes seen in psychosis risk samples are a consequence of pathological processes in a psychotic state; the results of current and ongoing trials in at risk for psychosis subjects (Kane and Correll, 2017) may shed further light on this.

4.3 Conclusions

In this cohort study did not find evidence of childhood PUFA levels being strongly associated with psychotic experiences and other psychosis outcomes in late adolescence. This may reflect that alterations may be a state phenomena or a
timing issue with levels being especially important during times when brain inflammatory and anti-inflammatory processes are key.

ACKNOWLEDGEMENTS

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.

The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors who will serve as guarantors for the contents of this paper. This research was funded by MRC grants G0701503 and MR/M006727/1.

This study was supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

CONFLICTS OF INTEREST

The authors report no conflicts of interest
REFERENCES

Amminger, G.P., Nelson, B., Markulev, C., Yuen, H.P., Schäfer, M.R., Berger, M., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I.B., Berger, G.E., Chen, E.Y.H., de Haan, L., Nieman, D.H., Nordentoft, M., Riecher-Rössler, A., Verma, S., Thompson, A., Yung, A.R., McGorry, P.D., 2020. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. Biol Psychiatry. 87(3):243-252.

Amminger, G.P., Schafer, M.R., Papageorgiou, K., Klier, C.M., Cotton, S.M., Harrigan, S.M., Mackinnon, A., McGorry, P.D., Berger, G.E., 2010. Long-Chain \( \omega \)-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial. Arch Gen Psychiatry 67(2), 146-154.

Amminger, G.P., Schafer, M.R., Schlogelhofer, M., Klier, C.M., McGorry, P.D., 2015. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun 6, 7934.

Baum, C.F., Schaffer, M.E., Stillman, S., 2002. IVREG2: Stata module for extended instrumental variables/2SLS and GMM estimation, S425401 ed. Boston College Department of Economics.

Bowen, E., Heron, J, Waylen, A, Wolke, D., 2005. Domestic violence risk during and after pregnancy: findings from a British longitudinal study. Bjog: An International Journal of Obstetrics and Gynaecology. 112(8), 1083-1089.

Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., Ness, A., Ring, S., Davey Smith, G., 2013. Cohort Profile: the 'children of the 90s'--
the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiology 42(1), 111-127.

Calder, P.C. 2017. Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochem Soc Trans 45:1105-1115.

Cannon, T.D., 2016. Microglial Activation and the Onset of Psychosis. Am J Psychiatry 173(1), 3-4.

Davey Smith, G., Hemani, G., 2014. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 23(R1), R89-98.

Dominguez, M.D., Wichers, M., Lieb, R., Wittchen, H.U., van Os, J., 2011. Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study. Schizophr Bull 37(1), 84-93.

Dyall, S.C., 2015. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci 7, 52-52.

Fisher, H.L., Caspi, A., Poulton, R., Meier, M.H., Houts, R., Harrington, H., Arseneault, L., Moffitt, T.E., 2013. Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study. Psychol Med 43(10):2077-86.

Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G., Henderson, J., Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S.M., Lawlor, D.A., 2013. Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiology 42(1), 97-110.
Golding, J., Northstone, K., Emmett, P., Steer, C., Hibbeln, J.R., 2012. Do ω-3 or other fatty acids influence the development of ‘growing pains’? A prebirth cohort study. BMJ Open 2(4).

Harris, W.S., Thomas, R.M., 2010. Biological variability of blood omega-3 biomarkers. Clin Biochem 43(3), 338-340.

Hedelin, M., Lof, M., Olsson, M., Lewander, T., Nilsson, B., Hultman, C.M., Weiderpass, E., 2010. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population. BMC Psychiatry 10, 38.

Hoen, W.P., Lijmer, J.G., Duran, M., Wanders, R.J., van Beveren, N.J., de Haan, L., 2013. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res 207(1-2), 1-12.

Horrobin, D.F., 1999. Lipids and schizophrenia. Brit J Psychiatry 175(88).

Horrobin, D.F., Glen, A.I., Vaddadi, K., 1994. The membrane hypothesis of schizophrenia. Schizophr Res 13(3), 195-207.

Horwood, J., Salvi, G., Thomas, K., Duffy, L., Gunnell, D., Hollis, C., Lewis, G., Menezes, P., Thompson, A., Wolke, D., Zammit, S., Harrison, G., 2008. IQ and non-clinical psychotic symptoms in 12-year-olds: results from the ALSPAC birth cohort. Brit J Psychiatry 193(3), 185-191.

Jeppesen, R., Benros, M.E., 2019. Autoimmune Diseases and Psychotic Disorders. Front Psychiatry 10, 131-131.

Kane, J.M., Correll, C.U., 2017. Ω-3 polyunsaturated fatty acids to prevent psychosis: The importance of replication studies. JAMA Psychiatry 74(1), 11-12.
Karlsson, H., Dalman, C., 2020. Epidemiological Studies of Prenatal and Childhood Infection and Schizophrenia. Current topics in behavioral neurosciences 44, 35-47.

Kaymaz, N., Drukker, M., Lieb, R., Wittchen, H.-U., Werbeloff, N., Weiser, M., Lataster, T., van Os, J., 2012. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. Psychol Med 42(11), 2239-2253.

Kelleher, I., Connor, D., Clarke, M.C., Devlin, N., Harley, M., Cannon, M., 2012a. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 42(09), 1857-1863.

Kelleher, I., Lynch, F., Harley, M., Molloy, C., Roddy, S., Fitzpatrick, C., Cannon, M., 2012b. Psychotic symptoms in adolescence index risk for suicidal behavior: findings from 2 population-based case-control clinical interview studies. Arch Gen Psychiatry 69(12), 1277-1283.

Kettunen, J., Demirkan, A., Wurtz, P., Draisma, H.H.M., Haller, T., Rawal, R., Vaarhorst, A., Kangas, A.J., Lyytikainen, L.P., Pirinen, M., Pool, R., Sarin, A.P., Soininen, P., Tukiainen, T., Wang, Q., Tiainen, M., Tynkkynen, T., Amin, N., Zeller, T., Beekman, M., Deelen, J., van Dijk, K.W., Esko, T., Hottenga, J.J., van Leeuwen, E.M., Lehtimaki, T., Mihailov, E., Rose, R.J., de Craen, A.J.M., Gieger, C., Kahonen, M., Perola, M., Blankenberg, S., Savolainen, M.J., Verhoeven, A., Viikari, J., Willemsen, G., Boomsma, D.I., van Duijn, C.M., Eriksson, J., Jula, A., Jarvelin, M.R., Kaprio, J., Metspalu, A., Raitakari, O., Salomaa, V., Slagboom, P.E., Waldenberger, M., Ripatti, S., Ala-Korpela, M., 2016. Genome-wide study for circulating
metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat Commun 7.

Khandaker, G.M., Cousins, L., Deakin, J., Lennox, B.R., Yolken, R., Jones, P.B., 2015. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2(3), 258-270.

Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., 2014. Association of serum interleukin 6 and c-reactive protein in childhood with depression and psychosis in young adult life: A population-based longitudinal study. JAMA Psychiatry 71(10), 1121-1128.

Kim, S.-W., Jhon, M., Kim, J.-M., Smesny, S., Rice, S., Berk, M., Klier, C.M., McGorry, P.D., Schäfer, M.R., Amminger, G.P., 2016. Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study. PloS one 11(3), e0151417.

Lepage, G., Roy, C.C., 1986. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 27(1), 114-120.

Liu, J.J., Green, P., John Mann, J., Rapoport, S.I., Sublette, M.E., 2015. Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease. Brain Res 1597, 220-246.

Masood, M.A., Salem, N., 2007. High-Throughput Analysis of Plasma Fatty Acid Methyl Esters Employing Robotic Transesterification and Fast Gas Chromatography. Lipids 43(2), 171.

McGorry, P.D., Nelson, B., Markulev, C., Yuen, H.P., Schaefer, M.R., Mossaheb, N., Schloegelhofer, M., Smesny, S., Hickie, I.B., Berger, G.E., Chen, E.Y.H., de Haan, L., Nieman, D.H., Nordentoft, M., Riecher-Rossler, A., Verma, S., Thompson, A., Yung, A.R., Amminger, G.P., 2017. Effect of omega-3 Polyunsaturated Fatty Acids in
Young People at Ultrahigh Risk for Psychotic Disorders The NEURAPRO Randomized Clinical Trial. JAMA Psychiatry 74(1), 19-27.

Medema, S., Mocking, R.J.T., Koeter, M.W.J., Vaz, F.M., Meijer, C., de Haan, L., van Beveren, N.J.M., Kahn, R., de Haan, L., van Os, J., Wiersma, D., Bruggeman, R., Cahn, W., Meijer, C., Myin-Germeys, I., 2016. Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls. Schizophr Bull 42(2), 358-368.

Mischoulon, D., Freeman, M.P., 2013. Omega-3 fatty acids in psychiatry. Psychiatr Clin North Am 36(1), 15-23.

Momtazmanesh, S., Zare-Shahabadi, A., Rezaei, N., 2019. Cytokine Alterations in Schizophrenia: An Updated Review. Frontiers in psychiatry 10, 892-892.

O’Neil, A., Quirk, S.E., Housden, S., Brennan, S.L., Williams, L.J., Pasco, J.A., Berk, M., Jacka, F.N., 2014. Relationship between diet and mental health in children and adolescents: a systematic review. Am J Public Health 104(10), e31-42.

Pawelczyk, T., Trafalska, E., Pawelczyk, A., Kotlicka-Antczak, M., 2017. Differences in omega-3 and omega-6 polyunsaturated fatty acid consumption in people at ultra-high risk of psychosis, first-episode schizophrenia, and in healthy controls. Early Interv Psychiatry, 11(6):498-508

Peet, M., Laugharne, J., Rangarajan, N., Horrobin, D., Reynolds, G., 1995. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 29(3), 227-232.

Perala, J., Suvisaari, J., Saarni, S.I., Kuoppasalmi, K., Isometsa, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppa, T., Harkanen, T., Koskinen, S., Lonqvist, J., 2007. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64(1), 19-28.
Reddy, R.D., Keshavan, M.S., Yao, J.K., 2004. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 30(4), 901-911.

Sanderson, E., Windmeijer, F., 2016. A weak instrument F-test in linear IV models with multiple endogenous variables. J Econometrics 190(2), 212-221.

Sarris, J., Logan, A.C., Akbaraly, T.N., Amminger, G.P., Balanzá-Martínez, V., Freeman, M.P., Hibbeln, J., Matsuoka, Y., Mischoulon, D., Mizoue, T., Nanri, A., Nishi, D., Ramsey, D., Rucklidge, J.J., Sanchez-Villegas, A., Scholey, A., Su, K.-P., Jacka, F.N., 2015. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry 2(3), 271-274.

Sheppard and, K.W., Cheatham, C.L., 2013. Omega-6 to omega-3 fatty acid ratio and higher-order cognitive functions in 7- to 9-y-olds: a cross-sectional study. Am J Clin Nutr. 98(3), 659-667.

Simopoulos, A.P., 2002. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 56(8), 365-379.

Smesny, S., Milleit, B., Hipler, U.C., Milleit, C., Schafer, M.R., Klier, C.M., Holub, M., Holzer, I., Berger, G.E., Otto, M., Nenadic, I., Berk, M., McGorry, P.D., Sauer, H., Amminger, G.P., 2014. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol Psychiatry 19(3), 317-324.

Soininen, P., Kangas, A.J., Wurtz, P., Suna, T., Ala-Korpela, M., 2015. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circulation. Cardiovascular Genetics 8(1), 192-206.

Soininen, P., Kangas, A.J., Wurtz, P., Tukiainen, T., Tynkkynen, T., Laatikainen, R., Jarvelin, M.R., Kahonen, M., Lehtimaki, T., Viikari, J., Raitakari, O.T., Savolainen,
M.J., Ala-Korpela, M., 2009. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 134(9), 1781-1785.

Sun, Q., Ma, J., Campos, H., Hankinson, S.E., Hu, F.B., 2007. Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. Am J Clin Nutr 86(1), 74-81.

Thesing, C.S., Bot, M., Milaneschi, Y., Giltay, E.J., Penninx, B., 2018. Omega-3 and omega-6 fatty acid levels in depressive and anxiety disorders. Psychoneuroendocrinology 87, 53-62.

van Os, J., Verdoux, H., Maurice-Tison, S., Gay, B., Liraud, F., Salamon, R., Bourgeois, M., 1999. Self-reported psychosis-like symptoms and the continuum of psychosis. Soc Psychiatry Psychiatr Epidemiol 34(9), 459-463.

Zammit, S., Kounali, D., Cannon, M., David, A.S., Gunnell, D., Heron, J., Jones, P.B., Lewis, S., Sullivan, S., Wolke, D., Lewis, G., 2013. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am J Psychiatry 170(7), 742-750.
| Measure (as % of total fatty acids) | 7 years | 16 years |
|-----------------------------------|---------|----------|
| **n-6**                           |         |          |
| LA                               | ✓        | ✓        |
| AA                               | ✓        |          |
| AdA                              | ✓        |          |
| OA                               | ✓        |          |
| Total n3                         | ✓        |          |
| **n-3**                           |         |          |
| ALA                              | ✓        |          |
| EPA                              | ✓        |          |
| DPA                              | ✓        |          |
| DHA                              | ✓        | ✓        |
| Total n6                         |          | ✓        |
| **ratio**                         |         |          |
| AA:EPA                           | ✓        |          |
| n6:n3                            | ✓        | ✓        |

**Note:** LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AdA, docosatetraenoic acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic acid (trivial name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; ALA, α-linolenic acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA, omega-3 docosapentaenoic acid (22:5n-3); DHA, docosahexaenoic acid (22:6n-3); total n3, total levels of omega-3 fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3 fatty acids.
Table 2. Prevalence of psychotic experiences at age 18 years

| Psychotic experience measure          | N     | N (%) with PE | N with fatty acid data at age 7 years | N (%) with PE | N with fatty acid data at age 16 years | N (%) with PE |
|--------------------------------------|-------|---------------|--------------------------------------|---------------|---------------------------------------|---------------|
| Definite/suspected versus none       | 4718  | 432 (9.16)    | 2844                                 | 229 (8.05)    | 2465                                  | 208 (8.44)    |
| Incident psychotic experiences versus none† | 3513  | 205 (5.84)    | 2308                                 | 140 (6.07)    | 1981                                  | 110 (5.55)    |
| Persistent psychotic experiences versus none†† | 4058  | 134 (3.30)    | 2631                                 | 61 (2.32)     | 2299                                  | 77 (3.35)     |
| Psychotic disorder versus none †††   | 4718  | 79 (1.67)     | 2844                                 | 43 (1.51)     | 2465                                  | 38 (1.54)     |

† Denotes individuals with definite or suspected psychotic experiences at age 18 years and no definite or suspected psychotic experiences at age 12 years

†† Denotes individuals with definite or suspected psychotic experiences at age 12 years and age 18 years

††† Psychotic disorder defined by psychotic experiences not attributable to the effects of sleep or fever that had occurred at least once per month over the previous 6 months and either caused severe distress, had a markedly negative impact on social or occupational function, or led to help seeking
Table 3. Unadjusted and adjusted association between fatty acid measures at age 7 years and psychotic experiences at age 18 years

| Outcome | Exposure | Unadjusted | Adjusted† |
|---------|----------|------------|-----------|
|         |          | OR (95% CIs) | P | OR (95% CIs) | P |
| Definite/suspected psychotic experiences versus none
| LA      | 0.993 (0.851, 1.159) | 0.931 | 1.001 (0.856, 1.172) | 0.986 |
| AA      | 0.853 (0.728, 0.999) | 0.049 | 0.873 (0.742, 1.026) | 0.100 |
| AdA     | 0.826 (0.702, 0.972) | 0.021 | 0.855 (0.723, 1.012) | 0.068 |
| OA      | 0.822 (0.697, 0.970) | 0.020 | 0.842 (0.711, 0.998) | 0.048 |
| Total n6| 0.938 (0.805, 1.094) | 0.415 | 0.954 (0.817, 1.114) | 0.553 |
| ALA     | 1.043 (0.896, 1.214) | 0.586 | 1.038 (0.891, 1.210) | 0.633 |
| EPA     | 0.977 (0.853, 1.164) | 0.967 | 0.987 (0.843, 1.156) | 0.871 |
| DPA     | 0.982 (0.841, 1.146) | 0.813 | 0.995 (0.848, 1.167) | 0.948 |
| DHA     | 0.978 (0.841, 1.139) | 0.776 | 1.016 (0.871, 1.186) | 0.835 |
| Total n3| 0.996 (0.855, 1.160) | 0.956 | 1.020 (0.874, 1.191) | 0.803 |
| AA:EPA  | 0.890 (0.758, 1.044) | 0.152 | 0.912 (0.777, 1.072) | 0.265 |
| n6:n3   | 0.968 (0.828, 1.132) | 0.688 | 0.956 (0.813, 1.124) | 0.585 |

Note: OR, odds ratio per standard deviation increase in fatty acid level; 95% CI, 95% confidence interval; P, p-value for association between fatty acid levels at age 7 years and psychotic experiences at age 18 years; LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AdA, docosatetraenoic acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic acid (trivial name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; ALA, α-linolenic acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA omega-3 docosapentaenoic acid (22:5n-3); DHA docosahexaenoic acid (22:6n-3); total n3, total levels of omega-3 fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3 fatty acids.
† Adjusted for gender; ethnic group; highest parental social class; maternal education; birth weight; family adversity index, body mass index at age 7 years; energy intake at age 7 years.
Table 4. Unadjusted and adjusted association between fatty acid measures at age 16 years and psychotic experiences at age 18 years

| Outcome                        | Exposure   | Unadjusted |  | Adjusted† |  |
|--------------------------------|------------|------------|---|------------|---|
|                                |            | OR (95% CIs) | P | OR (95% CIs) | P | N | N (%) with PE |
| Definite/suspected psychotic experiences versus none | LA         | 1.001 (0.850, 1.180) | 0.990 | 0.991 (0.840, 1.170) | 0.917 |
|                                | Total n6   | 0.944 (0.802, 1.111) | 0.488 | 0.938 (0.797, 1.106) | 0.447 |
|                                | DHA        | 0.871 (0.736, 1.032) | 0.110 | 0.882 (0.740, 1.051) | 0.162 |
|                                | Total n3   | 0.918 (0.779, 1.083) | 0.312 | 0.946 (0.799, 1.120) | 0.518 |
|                                | n6:n3      | 1.080 (0.926, 1.259) | 0.330 | 1.050 (0.895, 1.231) | 0.550 |

Note: OR, odds ratio per standard deviation increase in fatty acid level; 95% CI, 95% confidence interval; P, p-value for association between fatty acid levels at age 16 years and psychotic experiences at age 18 years; LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AdA, docosatetraenoic acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic acid (trivial name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; ALA, α-linolenic acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA omega-3 docosapentaenoic acid (22:5n-3); DHA docosahexaenoic acid (22:6n-3); total n3, total levels of omega-3 fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3 fatty acids.

† Adjusted for gender; ethnic group; highest parental social class; maternal education; birth weight; family adversity index, body mass index at age 16 years; energy intake at age 13 years.
Table 5. Multivariable Mendelian randomization results showing associations between total omega-3 and omega-6 fatty acids at age 16 years and definite/suspected psychotic experiences at age 18 years

| Exposure     | N   | OR (LCI, UCI) | P    | SW F | SW F P |
|--------------|-----|---------------|------|------|--------|
| **Instruments = unweighted allele scores** |     |               |      |      |        |
| Total omega-3 | 1922 | 1.14 (0.83, 1.57) | 0.421 | 8.41 | 0.004  |
| Total omega-6 | 1922 | 0.91 (0.75, 1.10) | 0.326 | 2.39 | 0.122  |
| **Instruments = weighted allele scores** |     |               |      |      |        |
| Total omega-3 | 1922 | 1.17 (0.82, 1.68) | 0.384 | 6.94 | 0.009  |
| Total omega-6 | 1922 | 0.91 (0.77, 1.09) | 0.307 | 2.73 | 0.099  |
| **Instruments = individual SNPs** |     |               |      |      |        |
| Total omega-3 | 543  | 1.04 (0.84, 1.30) | 0.698 | 0.96 | 0.511  |
| Total omega-6 | 543  | 1.00 (0.95, 1.05) | 0.904 | 1.26 | 0.206  |

*Note:* OR, odds ratio; LCI, lower 95% confidence level; UCI, upper 95% confidence level; SW, Sanderson-Windmeijer conditional F test of excluded instruments.
Figure 1: Omega 3 and Omega 6 metabolic pathway (from Calder, 2017)
Supplementary Table 1. Independent genetic variants used as genetic instruments for total omega-3 and total omega-6 fatty acid levels

| SNP       | Chr:BP       | A1/A2 | Freq A1 in ALSPAC | omega-3 beta<sup>a</sup> | omega-3 p value<sup>a</sup> | omega-6 beta<sup>b</sup> | omega-6 p value<sup>b</sup> | Used in allelic score |
|-----------|--------------|-------|-------------------|--------------------------|-----------------------------|--------------------------|--------------------------|-----------------------|
| rs638714  | 1:62906489   | T/G   | 0.36              | -0.052                   | 2.53E-04                    | -0.077                   | 4.78E-08                 | omega-6               |
| rs6547692 | 2:27734972   | A/G   | 0.55              | -0.078                   | 5.54E-10                    | -0.058                   | 3.62E-06                 | omega-3               |
| rs144064722| 4:73406173  | G/A   | 0.02              | 0.154                    | 1.04E-04                    | 0.237                    | 2.29E-09                 | omega-6               |
| rs2032885 | 5:74613918   | G/C   | 0.54              | -0.036                   | 5.55E-03                    | -0.072                   | 3.27E-08                 | omega-6               |
| rs149804  | 11:61538606  | G/A   | 0.39              | 0.085                    | 6.91E-11                    | 0.008                    | 5.51E-01                 | omega-3               |
| rs174475  | 11:61672645  | C/G   | 0.46              | 0.087                    | 6.59E-12                    | 0.017                    | 1.67E-01                 | omega-3               |
| rs10466588| 11:16610249  | G/A   | 0.08              | 0.096                    | 3.27E-06                    | 0.138                    | 1.76E-11                 | omega-6               |
| rs180327  | 11:116623659 | T/C   | 0.65              | -0.056                   | 9.40E-06                    | -0.092                   | 2.26E-13                 | omega-6               |
| rs564796  | 15:58665952  | A/T   | 0.39              | -0.040                   | 2.22E-03                    | -0.080                   | 1.20E-09                 | omega-6               |
| rs493258  | 15:58687880  | C/T   | 0.53              | -0.045                   | 2.75E-04                    | -0.078                   | 3.91E-10                 | omega-6               |
| rs12914626| 15:58738423  | T/C   | 0.71              | -0.050                   | 2.25E-04                    | -0.086                   | 2.50E-10                 | omega-6               |
| rs17321506| 16:56994528  | T/C   | 0.32              | 0.005                    | 7.10E-01                    | 0.076                    | 3.20E-08                 | omega-6               |
| rs11668477| 19:11195030  | G/A   | 0.21              | -0.028                   | 9.28E-02                    | -0.095                   | 6.57E-09                 | omega-6               |
| rs8100204 | 19:19393714  | A/G   | 0.11              | -0.122                   | 7.05E-10                    | -0.104                   | 1.43E-07                 | omega-3               |
| rs189741280| 19:19624481 | G/A   | 0.01              | -0.204                   | 7.38E-09                    | -0.138                   | 9.31E-05                 | omega-3               |
| rs150617279| 19:20139234 | A/T   | 0.06              | -0.121                   | 7.09E-09                    | -0.058                   | 5.80E-03                 | omega-3               |
| rs6857    | 19:45392254  | T/C   | 0.15              | 0.039                    | 1.64E-02                    | 0.115                    | 1.50E-12                 | omega-6               |
| rs72654473| 19:45414399  | A/C   | 0.10              | -0.036                   | 1.50E-01                    | -0.156                   | 5.97E-10                 | omega-6               |
| rs157594  | 19:45425175  | G/T   | 0.57              | 0.040                    | 4.81E-03                    | 0.096                    | 1.91E-11                 | omega-6               |

Note: SNP, single nucleotide polymorphism; Chr, chromosome; BP, base position; A1/A2, effect allele/alternative allele; Freq A1, frequency of the effect allele in the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort.

<sup>a</sup> SNP association effect size and p-value for omega-3 fatty acid levels as discovered in the Kettunen et al. (2016) fatty acid genome-wide association study meta-analysis.

<sup>b</sup> SNP association effect size and p-value for omega-6 fatty acid levels as discovered in the Kettunen et al. (2016) fatty acid genome-wide association study meta-analysis.
Supplementary Table 2. Total number of individuals with data available for confounder measures and proportion with psychotic experience data available at age 18 years.

| Confounder                             | Category / Age     | Total N | Category % | N with PE measure (% with PE)† | Missing PE measure†† % |
|----------------------------------------|--------------------|---------|------------|-----------------------------|------------------------|
| **Categorical measures**               |                    |         |            |                             |                        |
| Gender                                 | female             | 7219    | 48.60      | 2665 (10.43)                | 63.08                  |
|                                        | male               | 7635    | 51.40      | 2052 (7.50)                 | 73.12                  |
|                                        | total              | 14854   | 100.00     | 4717 (9.16)                 | 68.24                  |
| Ethnic group                           | Bangladeshi        | 7       | 0.06       | 1 (0.00)                    | 85.71                  |
|                                        | Black African      | 11      | 0.09       | 2 (0.00)                    | 81.82                  |
|                                        | Black Caribbean    | 76      | 0.61       | 21 (4.76)                   | 72.37                  |
|                                        | Black non-Africa, non-Caribbean | 44 | 0.35 | 8 (0.00) | 81.82 |
|                                        | Chinese            | 30      | 0.24       | 9 (0.00)                    | 70.00                  |
|                                        | Indian             | 54      | 0.44       | 16 (12.5)                   | 70.37                  |
|                                        | Pakistani          | 22      | 0.18       | 4 (0.00)                    | 81.82                  |
|                                        | White              | 12075   | 97.37      | 4186 (9.03)                 | 65.33                  |
|                                        | Other              | 82      | 0.66       | 29 (20.69)                  | 64.63                  |
|                                        | total              | 12401   | 100.00     | 4276 (9.05)                 | 65.52                  |
| Highest parental social class          | professional / managerial | 6328   | 55.09      | 2635 (7.36)                 | 58.36                  |
|                                        | non-professional / non-managerial | 5158   | 44.91      | 1481 (11.41)                | 71.29                  |
|                                        | total              | 11486   | 100.00     | 4116 (8.82)                 | 64.17                  |
| Maternal education – highest qualification | CSE                | 2527    | 20.23      | 497 (14.08)                 | 80.33                  |
|                                        | vocational         | 1229    | 9.84       | 311 (9.97)                  | 74.69                  |
|                                        | O level            | 4327    | 34.64      | 1463 (10.66)                | 66.19                  |
|                                        | A level            | 2801    | 22.42      | 1193 (5.95)                 | 57.41                  |
|                                        | degree             | 1609    | 12.88      | 827 (7.62)                  | 48.60                  |
|                                        | total              | 12493   | 100.00     | 4291 (9.11)                 | 65.65                  |
| **Continuous measures**                |                    |         |            |                             |                        |
| Birth weight                           | -                  | 13895   | -          | 4384 (9.19)                 | 68.45                  |
| Family adversity index                 | -                  | 12536   | -          | 4326 (8.95)                 | 65.49                  |
| Body mass index                        | 7 years            | 8201    | -          | 4033 (8.33)                 | 50.82                  |
|                                        | 16 years           | 5415    | -          | 3816 (8.41)                 | 29.53                  |
| Energy intake                          | 7 years            | 7279    | -          | 3720 (8.04)                 | 48.89                  |
|                                        | 13 years           | 6101    | -          | 3928 (8.43)                 | 35.62                  |

**Note:** PE, psychotic experiences; CSE, Certificate of Secondary Education.

† Denotes individuals with data available on the confounder measure and psychotic experiences at age 18 years, with percentage of individuals with definite or suspected psychotic experiences denoted in the parentheses.

†† Denotes the percentage of individuals with data available on the confounder measure but with missing data on psychotic experiences at age 18 years.
Supplementary Table 3. Summary statistics of fatty acid levels (non-transformed, expressed as percentages of total fatty acid content) at ages 7 and 16 years

| Fatty Acid | N   | Mean  | Std. Dev. | Min   | Max   |
|------------|-----|-------|-----------|-------|-------|
| Age 7 years |     |       |           |       |       |
| n-6        |     |       |           |       |       |
| LA         | 5565| 30.597| 3.175     | 16.631| 44.417|
| AA         | 5565| 6.436 | 1.322     | 2.538 | 12.275|
| AdA        | 5565| 0.248 | 0.051     | 0.091 | 0.526 |
| OA         | 5565| 0.186 | 0.049     | 0.016 | 0.479 |
| Total n6   | 5565| 37.467| 3.815     | 20.486| 51.562|
| n-3        |     |       |           |       |       |
| ALA        | 5565| 0.719 | 0.280     | 0.216 | 2.898 |
| EPA        | 5565| 0.644 | 0.211     | 0.118 | 4.687 |
| DPA        | 5565| 0.627 | 0.139     | 0.223 | 1.475 |
| DHA        | 5565| 1.889 | 0.524     | 0.599 | 5.079 |
| Total n3   | 5565| 3.879 | 0.796     | 1.497 | 10.839|
| ratio      |     |       |           |       |       |
| AA:EPA     | 5565| 10.713| 3.330     | 1.424 | 42.283|
| n-6:n-3    | 5565| 10.010| 2.087     | 3.037 | 24.119|
| Age 16 years |    |       |           |       |       |
| n-6        |     |       |           |       |       |
| LA         | 3356| 27.753| 2.708     | 15.080| 38.650|
| Total n6   | 3359| 33.989| 2.545     | 20.400| 42.220|
| n-3        |     |       |           |       |       |
| DHA        | 3360| 1.039 | 0.267     | 0.254 | 3.095 |
| Total n3   | 3360| 3.183 | 0.609     | 1.414 | 8.438 |
| ratio      |     |       |           |       |       |
| n-6:n-3    | 3357| 11.044| 2.184     | 3.232 | 26.330|

Note: LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AdA, docosatetraenoic acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic acid (trivial name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; ALA, α-linolenic acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA omega-3 docosapentaenoic acid (22:5n-3); DHA docosahexaenoic acid (22:6n-3); total n3, total levels of omega-3 fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3 fatty acids.
Supplementary Table 4. Unadjusted and adjusted association between fatty acid measures at age 7 years and other psychosis outcomes at age 18 years

| Outcome                              | Exposure | Unadjusted |           | Adjusted† |           | P   | N   | N (%) with PE |
|--------------------------------------|----------|------------|-----------|------------|-----------|-----|-----|----------------|
|                                      |          | OR (95% CIs) | P         | OR (95% CIs) | P         |     |     |                 |
| Incident psychotic experiences versus none⁠| LA       | 0.970 (0.798, 1.177) | 0.755 | 0.972 (0.799, 1.183) | 0.780 |
|                                      | AA       | 0.770 (0.628, 0.944) | 0.012 | 0.776 (0.630, 0.956) | 0.017 |
|                                      | AdA      | 0.774 (0.625, 0.957) | 0.018 | 0.784 (0.630, 0.975) | 0.029 |
|                                      | OA       | 0.770 (0.620, 0.956) | 0.018 | 0.782 (0.627, 0.976) | 0.029 |
|                                      | Total n6 | 0.890 (0.735, 1.079) | 0.235 | 0.897 (0.739, 1.089) | 0.274 |
|                                      | ALA      | 0.993 (0.811, 1.215) | 0.943 | 0.997 (0.813, 1.222) | 0.975 |
|                                      | EPA      | 1.051 (0.870, 1.270) | 0.604 | 1.043 (0.859, 1.265) | 0.672 |
|                                      | DPA      | 0.942 (0.772, 1.148) | 0.553 | 0.937 (0.764, 1.149) | 0.531 |
|                                      | DHA      | 0.964 (0.794, 1.171) | 0.713 | 0.966 (0.819, 1.211) | 0.967 |
|                                      | Total n3 | 0.976 (0.802, 1.189) | 0.811 | 0.965 (0.817, 1.216) | 0.972 |
|                                      | AA:EPA   | 0.786 (0.630, 0.979) | 0.032 | 0.801 (0.642, 0.999) | 0.049 |
|                                      | n6:n3    | 0.967 (0.794, 1.179) | 0.742 | 0.954 (0.779, 1.168) | 0.649 |
| Persistent psychotic experiences versus none⁠| LA       | 0.995 (0.750, 1.319) | 0.971 | 1.017 (0.762, 1.357) | 0.910 |
|                                      | AA       | 0.926 (0.696, 1.233) | 0.601 | 0.978 (0.730, 1.309) | 0.880 |
|                                      | AdA      | 0.951 (0.711, 1.271) | 0.733 | 1.036 (0.767, 1.399) | 0.819 |
|                                      | OA       | 0.949 (0.709, 1.270) | 0.724 | 1.019 (0.752, 1.381) | 0.905 |
|                                      | Total n6 | 0.969 (0.733, 1.282) | 0.827 | 1.007 (0.758, 1.336) | 0.963 |
|                                      | ALA      | 1.052 (0.800, 1.383) | 0.719 | 1.043 (0.791, 1.376) | 0.765 |
|                                      | EPA      | 0.938 (0.694, 1.268) | 0.677 | 0.922 (0.678, 1.254) | 0.605 |
|                                      | DPA      | 1.011 (0.763, 1.341) | 0.938 | 1.038 (0.775, 1.391) | 0.801 |
|                                      | DHA      | 0.915 (0.685, 1.221) | 0.545 | 0.976 (0.731, 1.305) | 0.872 |
|                                      | Total n3 | 0.946 (0.709, 1.262) | 0.706 | 0.986 (0.737, 1.318) | 0.922 |
|                                      | AA:EPA   | 0.918 (0.686, 1.227) | 0.563 | 0.963 (0.725, 1.279) | 0.792 |
|                                      | n6:n3    | 0.998 (0.750, 1.327) | 0.987 | 0.982 (0.729, 1.322) | 0.903 |
### Supplementary Table 4. continued

| Fatty Acid | Psychotic disorder versus none<sup>c</sup> | OR (95% CI) | P-value | OR (95% CI) | P-value |
|------------|-----------------------------------------|-------------|---------|-------------|---------|
| LA         | 1.000 (0.701, 1.425)                    | 0.998       |         | 1.039 (0.721, 1.497) | 0.838 |
| AA         | 1.117 (0.789, 1.582)                    | 0.532       |         | 1.187 (0.830, 1.697) | 0.347 |
| AdA        | 0.947 (0.660, 1.359)                    | 0.768       |         | 1.051 (0.726, 1.520) | 0.793 |
| OA         | 0.877 (0.604, 1.272)                    | 0.489       |         | 0.933 (0.635, 1.371) | 0.724 |
| Total n6   | 1.037 (0.727, 1.478)                    | 0.841       |         | 1.094 (0.761, 1.573) | 0.626 |
| ALA        | 0.922 (0.627, 1.356)                    | 0.680       |         | 0.891 (0.602, 1.218) | 0.564 |
| EPA        | 1.146 (0.849, 1.549)                    | 0.373       |         | 1.149 (0.852, 1.551) | 0.362 |
| DPA        | 1.273 (0.914, 1.772)                    | 0.153       |         | 1.385 (0.980, 1.957) | 0.065 |
| DHA        | 1.039 (0.741, 1.456)                    | 0.825       |         | 1.080 (0.769, 1.518) | 0.657 |
| Total n3   | 1.087 (0.777, 1.520)                    | 0.628       |         | 1.116 (0.798, 1.560) | 0.523 |
| AA:EPA     | 0.737 (0.487, 1.115)                    | 0.148       |         | 0.753 (0.493, 1.151) | 0.191 |
| n6:n3      | 0.833 (0.568, 1.222)                    | 0.350       |         | 0.825 (0.554, 1.228) | 0.343 |

Note: OR, odds ratio per standard deviation increase in fatty acid level; 95% CI, 95% confidence interval; P, p-value for association between fatty acid levels at age 7 years and psychotic experiences at age 18 years; LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AdA, docosatetraenoic acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic acid (trivial name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; ALA, α-linolenic acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA omega-3 docosapentaenoic acid (22:5n-3); DHA docosahexaenoic acid (22:6n-3); total n3, total levels of omega-3 fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3 fatty acids.

<sup>a</sup> Denotes individuals with definite or suspected psychotic experiences at age 18 years and no definite or suspected psychotic experiences at age 12 years

<sup>b</sup> Denotes individuals with definite or suspected psychotic experiences at age 12 years and age 18 years

<sup>c</sup> Psychotic disorder defined by psychotic experiences not attributable to the effects of sleep or fever that had occurred at least once per month over the previous 6 months and either caused severe distress, had a markedly negative impact on social or occupational function, or led to help seeking

† Adjusted for gender; ethnic group; highest parental social class; maternal education; birth weight; family adversity index, body mass index at age 7 years; energy intake at age 7 years, with the exception of analyses of incident psychotic experiences and persistent psychotic experiences where ethnic group wasn't used as a covariate as it did not vary with the outcome.
## Supplementary Table 5. Unadjusted and adjusted association between fatty acid measures at age 16 years and psychotic experiences at age 18 years

| Outcome                         | Exposure | Unadjusted OR (95% CIs) | P     | Adjusted† OR (95% CIs) | P     | N    | N (%) with PE |
|---------------------------------|----------|-------------------------|-------|-------------------------|-------|------|---------------|
| Incident psychotic experiences versus none<sup>a</sup> | LA       | 0.968 (0.783, 1.196)    | 0.762 | 0.970 (0.783, 1.201)    | 0.778 |      |               |
|                                 | Total n6 | 0.874 (0.710, 1.075)    | 0.203 | 0.877 (0.711, 1.081)    | 0.218 |      |               |
|                                 | DHA      | 0.858 (0.688, 1.070)    | 0.174 | 0.862 (0.685, 1.084)    | 0.205 | 1663 | 90 (5.41)     |
|                                 | Total n3 | 0.829 (0.663, 1.037)    | 0.101 | 0.846 (0.674, 1.064)    | 0.153 |      |               |
|                                 | n6:n3    | 1.145 (0.943, 1.390)    | 0.173 | 1.127 (0.922, 1.379)    | 0.244 |      |               |
| Persistent psychotic versus none<sup>b</sup> | LA       | 1.007 (0.774, 1.311)    | 0.959 | 0.996 (0.765, 1.297)    | 0.975 |      |               |
|                                 | Total n6 | 0.995 (0.764, 1.295)    | 0.968 | 0.988 (0.759, 1.287)    | 0.930 |      |               |
|                                 | DHA      | 0.934 (0.718, 1.215)    | 0.613 | 0.965 (0.736, 1.265)    | 0.795 | 1919 | 58 (3.02)     |
|                                 | Total n3 | 1.000 (0.774, 1.291)    | 0.999 | 1.045 (0.806, 1.355)    | 0.740 |      |               |
|                                 | n6:n3    | 1.014 (0.788, 1.306)    | 0.911 | 0.972 (0.749, 1.262)    | 0.833 |      |               |
| Psychotic disorder versus none<sup>c</sup> | LA       | 1.502 (1.034, 2.183)    | 0.033 | 1.442 (0.987, 2.107)    | 0.059 |      |               |
|                                 | Total n6 | 1.676 (1.114, 2.522)    | 0.013 | 1.619 (1.068, 2.454)    | 0.023 |      |               |
|                                 | DHA      | 0.816 (0.546, 1.222)    | 0.324 | 0.852 (0.554, 1.312)    | 0.468 | 1974 | 28 (1.42)     |
|                                 | Total n3 | 0.939 (0.644, 1.370)    | 0.745 | 1.029 (0.695, 1.524)    | 0.886 |      |               |
|                                 | n6:n3    | 1.243 (0.896, 1.724)    | 0.192 | 1.161 (0.817, 1.648)    | 0.405 |      |               |

**Note:** OR, odds ratio per standard deviation increase in fatty acid level; 95% CI, 95% confidence interval; P, p-value for association between fatty acid levels at age 16 years and psychotic experiences at age 18 years; LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AAdA, docosatetraenoic acid (trivial name adrenic acid; 22:4n-6); OA, omega-6 docosapentaenoic acid (trivial name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; ALA, α-linolenic acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA omega-3 docosapentaenoic acid (22:5n-3); DHA docosahexaenoic acid (22:6n-3); total n3, total levels of omega-3 fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3 fatty acids.

<sup>a</sup> Denotes individuals with definite or suspected psychotic experiences at age 18 years and no definite or suspected psychotic experiences at age 12 years

<sup>b</sup> Denotes individuals with definite or suspected psychotic experiences at age 12 years and age 18 years

<sup>c</sup> Psychotic disorder defined by psychotic experiences not attributable to the effects of sleep or fever that had occurred at least once per month over the previous 6 months and either caused severe distress, had a markedly negative impact on social or occupational function, or led to help seeking

† Adjusted for gender; ethnic group; highest parental social class; maternal education; birth weight; family adversity index, body mass index at age 16 years; energy intake at age 13 years.
Supplementary Table 6: Multivariable Mendelian randomization results showing associations between total omega-3 and omega-6 fatty acids at age 16 years and psychotic experiences at age 18 years

| Exposure | Outcome | N     | OR (LCI, UCI) | P     | SW F | SW F P   |
|----------|---------|-------|---------------|-------|-------|-----------|
| **Instruments = unweighted allele scores** |
| Total omega-3 | Incident psychotic experiences versus none<sup>a</sup> | 1629 | 0.90 (0.72, 1.12) | 0.343 | 8.97  | 0.003     |
| Total omega-6 | Incident psychotic experiences versus none<sup>a</sup> | 1629 | 0.98 (0.87, 1.11) | 0.767 | 2.77  | 0.096     |
| Total omega-3 | Persistent psychotic experiences versus none<sup>b</sup> | 1889 | 1.16 (0.94, 1.43) | 0.179 | 10.32 | 0.001     |
| Total omega-6 | Persistent psychotic experiences versus none<sup>b</sup> | 1889 | 0.95 (0.85, 1.06) | 0.367 | 2.66  | 0.103     |
| Total omega-3 | Psychotic disorder versus none<sup>c</sup> | 1992 | 1.02 (0.93, 1.12) | 0.727 | 8.41  | 0.004     |
| Total omega-6 | Psychotic disorder versus none<sup>c</sup> | 1992 | 1.00 (0.94, 1.06) | 0.945 | 2.39  | 0.122     |
| **Instruments = weighted allele scores** |
| Total omega-3 | Incident psychotic experiences versus none<sup>a</sup> | 1629 | 0.89 (0.69, 1.14) | 0.353 | 6.78  | 0.009     |
| Total omega-6 | Incident psychotic experiences versus none<sup>a</sup> | 1629 | 0.98 (0.89, 1.09) | 0.765 | 3.23  | 0.073     |
| Total omega-3 | Persistent psychotic experiences versus none<sup>b</sup> | 1889 | 1.19 (0.93, 1.53) | 0.159 | 8.23  | 0.004     |
| Total omega-6 | Persistent psychotic experiences versus none<sup>b</sup> | 1889 | 0.96 (0.87, 1.05) | 0.362 | 3.16  | 0.076     |
| Total omega-3 | Psychotic disorder versus none<sup>c</sup> | 1992 | 1.03 (0.93, 1.15) | 0.554 | 6.94  | 0.009     |
| Total omega-6 | Psychotic disorder versus none<sup>c</sup> | 1992 | 1.00 (0.95, 1.05) | 0.996 | 2.73  | 0.099     |
| **Instruments = individual SNPs** |
| Total omega-3 | Incident psychotic experiences versus none<sup>a</sup> | 441  | 1.08 (0.86, 1.36) | 0.498 | 0.74  | 0.765     |
| Total omega-6 | Incident psychotic experiences versus none<sup>a</sup> | 441  | 0.98 (0.94, 1.02) | 0.347 | 1.34  | 0.159     |
| Total omega-3 | Persistent psychotic experiences versus none<sup>b</sup> | 508  | 0.93 (0.80, 1.10) | 0.415 | 1.11  | 0.338     |
| Total omega-6 | Persistent psychotic experiences versus none<sup>b</sup> | 508  | 1.02 (0.99, 1.05) | 0.267 | 1.39  | 0.132     |
| Total omega-3 | Psychotic disorder versus none<sup>c</sup> | 543  | 0.96 (0.88, 1.05) | 0.366 | 0.96  | 0.511     |
| Total omega-6 | Psychotic disorder versus none<sup>c</sup> | 543  | 1.01 (0.98, 1.03) | 0.709 | 1.26  | 0.206     |

Note: OR, odds ratio; LCI, lower 95% confidence level; UCI, upper 95% confidence level; SW, Sanderson-Windmeijer conditional F test of excluded instruments

<sup>a</sup> Denotes individuals with definite or suspected psychotic experiences at age 18 years and no definite or suspected psychotic experiences at age 12 years

<sup>b</sup> Denotes individuals with definite or suspected psychotic experiences at age 12 years and age 18 years

<sup>c</sup> Psychotic disorder defined by psychotic experiences not attributable to the effects of sleep or fever that had occurred at least once per month over the previous 6 months and either caused severe distress, had a markedly negative impact on social or occupational function, or led to help seeking
Supplementary Figure 1. Association between fatty acid measures and definite/suspected psychotic experiences at age 18 years

**Note:** SD, standard deviation; LA, linoleic acid (18:2n-6); AA, arachidonic acid (20:4n-6); AdA, docosatetraenoic acid (trivial name adenoc acid; 22:4n-6); OA, omega-6 docosapentaenoic acid (trivial name osbond acid; 22:5n-6); total n6, total levels of omega-6 fatty acids; ALA, α-linolenic acid (18:3n-3); EPA, eicosapentaenoic acid (20:5n-3); DPA omega-3 docosapentaenoic acid (22:5n-3); DHA docosahexaenoic acid (22:6n-3); total n3, total levels of omega-3 fatty acids; n6:n3, ratio of total levels of omega-6 to total levels of omega-3 fatty acids; error bars denote upper and lower 95% confidence interval.
Supplementary methods

Genetic data

Genetic data were acquired using the Illumina HumanHap550 quad genome-wide single nucleotide polymorphism (SNP) genotyping platform from 9912 participants. Individuals were excluded from further analysis on the basis of gender mismatches, minimal or excessive heterozygosity, disproportionate levels of individual missingness (>3%), evidence of cryptic relatedness (>5% of alleles identical by descent), and being of non-European ancestry (assessed by multidimensional scaling analysis including HapMap 2 individuals). SNPs with a minor allele frequency (MAF) of < 1%, Impute2 information quality metric of < 0.8, a call rate of < 95% or evidence for violations of Hardy-Weinberg equilibrium (p value < 5 x 10^{-7}) were removed. Imputation of the target data was performed using Impute V2.2.2 against the 1000 genomes reference panel (Phase 1, Version 3; all polymorphic SNPs excluding singletons), using 2186 reference haplotypes (including non-Europeans). Following quality control assessment and imputation, genetic data was available for 8252 ALSPAC individuals.

Fatty acid genetic instruments

Genetic instruments were derived using summary statistics from the recent Kettunen et al. (2016) meta-analysis of genome-wide association studies (GWAS) of blood levels of DHA, LA, total omega-3 and total omega-6 fatty acids measured using a high-throughput NMR metabolomics platform in up to 24,925 individuals (Kettunen et al. 2016). Based on the GWAS meta-analysis summary statistics, a list of SNPs that were associated with total omega-3 and total omega-6 fatty acid levels at a genome-wide level of significance (p value ≤ 5e^{-8}) was extracted. This list was then harmonised to the ALSPAC genetic data (based on SNP availability and equivalence of alleles) and pruned for linkage disequilibrium based on a r^2 ≥ 0.1, 3000 kb window size and 1000 genomes reference panel (Phase 1, Version 3) using the PLINK (v1.9) (Purcell et al., 2007; Chang et al. 2015) 'indep-pairwise' command. This resulted in a final list of 19 independent SNPs that were associated with total omega-3 and/or total omega-6 fatty acid levels at a genome-wide level of significance (Supplementary Table 1). For the
MVMR analysis, SNPs were either used as individual instruments, where each ALSPAC individual had 0, 1 or 2 fatty acid level increasing alleles, or summarised into 2 allelic scores (one for total omega-3 and one for total omega-6) based on the sum of the number of PUFA level increasing alleles each ALSPAC individual possessed. Unweighted and weighted (by discovery GWAS effect sizes) allelic scores were generated using the PLINK ‘score’ command.

Confounders
For the non-genetic analyses, the following confounders were able to be considered due to their potential influence on both the exposure and outcome:

Sociodemographic factors:

*Gender; Ethnic group; Highest Parental Social Class; Maternal Education*

A number of socio-demographic variables were included as potential confounders. Questionnaires completed by the parents during the antenatal period provided information on: child’s ethnic background (non-white vs. white); parental social class based on the higher of the mother or partner’s occupational social class (using the 1991 Office of Population Census and Statistics (OPCS) classification (Office of Population Census and Statistics (Office of Population Censuses and Surveys, 1991) and dichotomised into manual and non-manual); Maternal Education was also dichotomised (A levels/degree or equivalent (higher education) v O-level/CSE’s (Certificate of Secondary Education - lowest UK school-leaving qualifications))

*Other confounding factors*

*Birth Weight; Body Mass Index (BMI) at 7 and at 16* (The child’s BMI was calculated at the same clinic when the blood sample were taken for the FA analysis); *Energy intake at 7 and at 13* (The child’s overall energy intake was calculated from the completion of the Food Frequency Questionnaire as part of the interview aged 7 and 13). Finally, a *Family Adversity Index* ((FAI) indicating multiple family risk factors were assessed during pregnancy with the Family Adversity Index (Bowen et al., 2005). The FAI consists of 17 items taken from questionnaires that were administered throughout pregnancy (8
weeks gestation, 12 weeks gestation, 18 weeks gestation and 32 weeks gestation). The index was based on a series of measures describing aspects of family functioning covering: young maternal age (<21 years) at first pregnancy / child birth; Housing (e.g. inadequacy: crowding index / periods of homelessness); Financial difficulties; problematic partner relationship, maternal affective disorder (depression, anxiety, suicidality), substance abuse of drugs or involvement in crime (i.e. in trouble with police/convictions). If adversity was present in an item this was rated as 1 and then totaled across the 17 items.

References

1. Kettunen J, Demirkan A, Wurtz P, et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of Lpa. *Nat Commun.* 2016;7.

2. Purcell S, Neale B, Todd-Brown K, et al. Plink: A tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007;81:559-575.

3. Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation plink: Rising to the challenge of larger and richer datasets. *Gigascience.* 2015;4.

4. Office of Population Censuses and Surveys, *Standard Occupational Classification.* 1991, London: Her Majesty's Stationery Office.

5. Bowen, E., Heron, J, Waylen, A, Wolke, D., *Domestic violence risk during and after pregnancy: findings from a British longitudinal study.* Bjog: An International Journal of Obstetrics and Gynaecology., 2005. 112(8):1083-1089.